We are live on ! Find out more
NVCT icon

Nuvectis Pharma
NVCT

8 hedge funds and large institutions have $4.65M invested in Nuvectis Pharma in 2022 Q1 according to their latest regulatory filings, with 8 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

4.94% more ownership

Funds ownership: 0% → 4.94% (+4.9%)

Holders
8
Holders Change
+8
Holders Change %
–
% of All Funds
0.13%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
8
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
RC
Ronit Capital
United Kingdom
+$3.83M
2
Millennium Management
Millennium Management
New York
+$293K
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$103K
4
VF
Virtu Financial
New York
+$79.1K
5
BlackRock
BlackRock
New York
+$54.8K

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
RC
1
Ronit Capital
United Kingdom
$4.08M +$3.83M +550,000 New
Millennium Management
2
Millennium Management
New York
$312K +$293K +42,160 New
Geode Capital Management
3
Geode Capital Management
Massachusetts
$109K +$103K +14,822 New
VF
4
Virtu Financial
New York
$84K +$79.1K +11,365 New
BlackRock
5
BlackRock
New York
$59K +$54.8K +7,872 New
TRCT
6
Tower Research Capital (TRC)
New York
$13K +$12.2K +1,750 New
UBS Group
7
UBS Group
Switzerland
$1K +$981 +141 New
Wells Fargo
8
Wells Fargo
California
– +$139 +20 New

NVCT Hedge Fund Activity: Q1 2022 in Review

8 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Nuvectis Pharma (NVCT) for Q1 2022, worth a combined $4.65M.

Buyers outnumbered sellers: 8 funds opened new NVCT positions and 0 closed out — a net gain of 8 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Ronit Capital, opening a new position worth an estimated $3.83M.

  • 8 institutional investors held Nuvectis Pharma (NVCT) as of Q1 2022, up from 0 in Q4 2021.
  • Funds reported $4.65M of Nuvectis Pharma stock for Q1 2022.
  • 8 funds opened new Nuvectis Pharma positions in Q1 2022 and 0 closed out, a net change of +8 holders.
  • The largest Nuvectis Pharma buyer in Q1 2022 was Ronit Capital, an estimated $3.83M added.

Based on aggregated 13F filings for Q1 2022.